<DOC>
	<DOC>NCT01136551</DOC>
	<brief_summary>The purpose of this study is to develop oral controlled release formulation of Huperzine A that will provide optimal pharmacokinetic profile of the drug enhancing safety and compliance, as possible cure to neurodegenerative disorders.</brief_summary>
	<brief_title>Comparative Bioavailability Study of an Immediate Release and Controlled Release Oral Formulations of Huperzine A</brief_title>
	<detailed_description />
	<mesh_term>Huperzine A</mesh_term>
	<criteria>1. Healthy males between the age of 18 and 35, inclusive (ASA = 1) 2. Body weight &gt; 50 kg 3. Subject has a BMI less than 27 and more than 20 4. Participants should be able to ingest oral medication 5. The ability to understand and sign a written informed consent form, prior to participation and the willingness to comply with all study requirements 1. History of drug sensitivity or drug allergy 2. History of sensitivity to eggs 3. Subject has a BMI less than 20 and more than 27 4. Previous participation in an investigational trial involving administration of any investigational compound within 1 month prior to the current study 5. History of alcoholism or drug addiction 6. Any medication taken including overthecounter medications and herbal products within 14 days of commencing study drug dosing with the exception of vitamins and/or paracetamol. When a concomitant medication is necessary, this will be reviewed by the investigator and if not contraindicated, may be continued at the same dose and frequency during the study period 7. History of clinically important illness (ASA&gt;1); Disorders or conditions that could affect the absorption, distribution, metabolism and/or excretion of drugs (e.g. malabsorption, edema, renal or hepatic insufficiency) 8. Inability to relate to and/or cooperate with the investigators 9. Blood loss or donation greater than 200ml in the 3 months prior to the trial 10. Exhausting physical exercise during the previous 48 hours to drug administration 11. Subjects who have smoked or used nicotinecontaining products within 6 months prior to study entry</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Pharmacokinetic profile of controlled release formulation of Huperzine A</keyword>
	<keyword>Bioequivalence of Huperzine A IR formulation and CR formulation</keyword>
</DOC>